← Back to Clinical Trials
Recruiting NCT07306065

NCT07306065 University of Central Florida Music Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07306065
Status Recruiting
Phase
Sponsor University of Central Florida
Condition Alzheimers Disease
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-08-28
Primary Completion 2026-03

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Music intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2025-08-28 with a primary completion date of 2026-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to scientifically validate the impact of music therapy on Alzheimer's disease (AD) by analyzing molecular biomarkers in salivary exosomes. Exosomes are extracellular vesicles that carry molecular signals from brain cells, providing a non-invasive method to assess physiological changes.

Eligibility Criteria

Inclusion Criteria: * 50 years old or older. * 20 adults with no mild-cognitive impairment * 20 adults with mild-cognitive impairment * 20 adults with Alzheimer's disease/ dementia. * participant or the participant's legally authorized representative must be able to read or speak English and agree to comply with study procedures. * pregnant women may chose to participate Exclusion Criteria: * 49 years and younger * prisoners * unable to understand English and provide consent

Contact & Investigator

Central Contact

Amoy Fraser, PhD, CCRP, PMP

✉ Amoy.Fraser@ucf.edu

📞 14072668742

Principal Investigator

Kiminobu Sugaya, PhD

PRINCIPAL INVESTIGATOR

University of Central Florida

Frequently Asked Questions

Who can join the NCT07306065 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, studying Alzheimers Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07306065 currently recruiting?

Yes, NCT07306065 is actively recruiting participants. Contact the research team at Amoy.Fraser@ucf.edu for enrollment information.

Where is the NCT07306065 trial being conducted?

This trial is being conducted at Orlando, United States.

Who is sponsoring the NCT07306065 clinical trial?

NCT07306065 is sponsored by University of Central Florida. The principal investigator is Kiminobu Sugaya, PhD at University of Central Florida. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology